Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial in those with methylthioadenosine phosphorylase (MTAP)-deleted solid tumours ...

About 15% of all cancers have co-deletion of both the MTAP and CDKN2A genes, which results in sensitization to MAT2A inhibitors, thus opening a therapeutic window in these cancer types. MAT2A ...

"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt ...

“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].” ...

“We are interested in going after MTAP-/- tumors in non-small cell lung cancer (NSCLC), mesothelioma, esophageal, bladder cancers etcetera,” Michelle Chen, PhD, Insilico’s chief business ...

A new research paper titled "Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss" has been published in Oncotarget. Homozygous deletion ...